Bifosfonatos por vía oral: consideraciones en el área odontológica
DOI:
https://doi.org/10.35954/SM2015.34.2.4Palabras clave:
Bifosfonatos; Osteonecrosis de los maxilares asociada a bifosfonatos; Reabsorción ÓseaResumen
Los bifosfonatos, especialmente los administrados por vía intravenosa, han sido utilizados desde la década de los 90 para el tratamiento de enfermedades que involucran tejido óseo. Una de las complicaciones más frecuentes de su uso es la osteonecrosis de los maxilares. Los casos de osteonecrosis de mandíbula asociados a bifosfonatos son generalmente relacionados a traumas menores, por ejemplo la realización de extracciones dentarias y la consiguiente exposición de hueso al medio oral, aunque la etiopatogenia aún no está totalmente determinada. El tratamiento de estas lesiones es variado y se adecúa a la etapa en que se encuentran, aunque es primordial la prevención en cada una de ellas.
Descargas
Métricas
Citas
(1) Consolaro A. The use of bisphosphonates does not contraindicate orthodontic and other types of treatment! Dental Press J Orthod 2014; 19(4):18-26.
(2) Kumar V, Sinha R. Evolution and etiopathogenesis of bisphosphonates induced osteonecrosis of the jaw. N Am J Med Sci 2013; 5(4):260-5.
(3) Kalyan S, Wang J, Quabius E, Huck J, Wiltfang J, Baines J, et al. Systemic immunity shapes the oral microbiome and susceptibility to bisphosphonateassociated osteonecrosis of the jaw. J Transl Med 2015; 13: 212.
(4) Passeri LA, Bértolo MB, Abuabara A. Bisphosphonate -related osteonecrosis of the jaws. Rev Bras Reumatol 2011; 51(4):401-3, 407.
(5) Borgioli A, Viviani C, Duvina M, Brancato L, Spinelli G, Brandi ML, et al. Biphosphonates-related osteonecrosis of the jaw: Clinical and physiopathological considerations. Ther Clin Risk Manag 2009; 5(1):217-27.
(6) Khan A. Bisphosphonate-associated osteonecrosis of the jaw. Can Fam Physician 2008; 54(7):1019-21.
(7) Gómez-Moreno G, Arribas-Fernandez M, FernandezGuerrero M, Boquete-Castro A, Aguilar-Salvatierra A, Guardia J, et al. Bisphosphonate-associated osteonecrosis of the jaw 2 years after teeth extractions: a case report solved with non-invasive treatment. Eur Rev Med Pharmacol Sci 2014; 18 (9):1391-7.
(8) Kumar V; Kumar A. Nitrogen containing bisphosphonates associated osteonecrosis of the jaws: A review for past 10 year literature. Dent Res J (Isfahan). 2014; 11(2):147–153.
(9) Manzon L,Ettorre E, Viscogliosi G, Ippoliti S, Filiaci F, Ungari C, et al. Bisphosphonate therapy and osteonecrosis of the jaw complicated with a temporal abscess in an elderly woman with rheumatoid arthritis: a case report. Clin Interv Aging 2014; 9:1409-1413.
(10) Günaldi M, Usul Afsar C, Bozkurt Duman B, Oguz Kara I, Tatli U, and Sahin B. Effect of the cumulative dose of zoledronic acid on the pathogenesis of osteonecrosis of the jaws. Oncol Lett 2015; 10(1): 439-442.
(11) Zee Man Wat W. Current perspectives on bisphosphonate treatment in Paget's disease of bone. Ther Clin Risk Manag 2014; 10: 977-983.
(12) Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008; 83(9):1032-45.
(13) Oteri G, Bramanti E, Nigrone V, Cicciu M. Decayed, Missing, and Filled Teeth Index and Periodontal Health in Osteoporotic Patients Affected by BRONJ: An Observational Study. J Osteoporos 2013; 2013: 231289.
(14) Rasmusson L; Abtahi J. Bisphosphonate Associated Osteonecrosis of the Jaw: An Update on Pathophysiology, Risk Factors, and Treatment. Int J Dent 2014; 2014: 471035.
(15) Miniello TG, Araújo JP, Lopes RN, Alves FA. Osteonecrosis related to once-yearly zoledronic acid treatment in an osteoporotic patient after dental implant. Braz Dent J 2015; 26(1):86-8.
(16) Sigua-Rodriguez E, da Costa Ribeiro R, Ramos de Brito A, Alvarez-Pinzon N, de Albergaria-Barbosa J. Bisphosphonate-Related Osteonecrosis of the Jaw: A Review of the Literature. Int J Dent 2014; 2014: 192320.
(17) Scheper MA, Badros A, Chaisuparat R, Cullen KJ, Meiller TF. Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potencial mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol 2009; 144(5):667-76.
(18) Adler RA, Gill RS. Clinical utility of denosumab for treatment of bone loss in men and women. Clin Interv Aging 2011; 6:119-24.
(19) Kuiper JW, Forster C, Sun C, Peel S, Glogauer M. Zoledronate and pamidronate depress neutrophil functions and survival in mice. Br J Pharmacol 2012; 165(2):532-9.
(20) Roldan C; Paniagua L, Complications of New Medications. West J Emerg Med 2015; 16(1):154-156.
(21) Vescovi P, Meleti M, Merigo E, Manfredi M, Fornaini C, Guidotti R, et al. Case series of 589 tooth extractions in patients under bisphosphonates therapy. Proposal of a clinical protocol supported by Nd:YAG low-level laser therapy. Med Oral Patol Oral Cir Bucal 2013; 18(4):e680-5.
(22) Paulo S, Abrantes A, Laranjo M, Carvalho L, Serra A, Botelho M, et al. Bisphosphonate-Related Osteonecrosis of the Jaw: Specificities. Oncol Rev 2014; 8(2):254.
(23) Lorenzo S, Trapassi A, Corradino B, Cordova A. Histology of the Oral Mucosa in Patients with BRONJ at III Stage: A Microscopic Study Proves the Unsuitability of Local Mucosal Flaps. J Clin Med Res 2013; 5(1):22-5.
(24) Ro C, Cooper O. Bisphosphonate drug holiday: choosing appropriate candidates. Curr Osteoporos Rep 2013; 11(1):45-51.
(25) McGreevy C, Williams D. Safety of drugs used in the treatment of osteoporosis. Ther Adv Drug Saf 2011; 2(4):159-72.
(26) Otto S, Sotlar K, Ehrenfeld M, Pautke. Osteonecrosis of the jaw as a possible rare side effect of annual bisphosphonate administration for osteoporosis: A case report. J Med Case Rep 2011; 5:477.
(27) Mawardi H. Arole of oral bacteria in bisphosphonateinduced osteonecrosis of the jaw. J Dent Res 2011; 90(11):1339-45.
(28) Takaishi Y, Ikeo T, Nakajima M, Miki T, Fujita T. A pilot case-control study on the alveolar bone density measurement in risk assessment for bisphosphonaterelated osteonecrosis of the jaw. Osteoporos Int 2010; 21(5):815-25.
(29) Carey JJ, Palomo L. Bisphosphonates and osteonecrosis of the jaw: innocent association or significant risk? Cleve Clin J Med 2008; 75(12):871-9.
(30) Kang B, Cheong S, Chaichanasakul T, Bezouglaia O, Atti E, Dry SM, et al. Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice. J Bone Miner Res 2013; 28(7):1631-40.
(31) Albu S. Bisphosphonates and osteonecrosis of the maxilla. QJM 2014; 107(4):311.
(32) Kos M. Incidence and risk predictors for osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. Arch Med Sci 2015; 11(2):319–324.
(33) Flichy-Fernández A. Bisphosphonates and dental implants: current problems. Med Oral Patol Oral Cir Bucal 2009; 14(7):E355-60.
(34) Baillargeon J, Kuo YF, Lin YL, Wilkinson GS, Goodwin JS.. Osteonecrosis of the jaw in older osteoporosis patients treated with intravenous bisphosphonates. Ann Pharmacother 2011; 45(10):1199-1206.
(35) Hechmati G. Brett Hauber A, Arellano J, Mohamed, Qian Y, Gatta F, et al. Patient's preferences for bone metastases treatments in France, Germany and the United Kingdom. Support Care Cancer 2015; 23: 21-28.
(36) Mercer E, Norton T, Woo S, Treister N, Dodson TB, Solomon DH.. Ninety-one osteoporosis patients affected with bisphosphonate-related osteonecrosis of the jaw: a case series. Calcif Tissue Int 2013; 93(3):241-8.
(37) Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS. Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med 2008; 121(6):475-483.
(38) Beninati , Pruneti R, Ficarra G. Bisphosphonaterelated osteonecrosis of the jaws (Bronj). Med Oral Patol Oral Cir Bucal 2013; 18(5):e752-8.
(39) Gallay L, Bodard AG, Chidiac C, Ferry T. Bilateral bisphosphonate-related osteonecrosis of the jaw with left chronic infection in an 82-year-old woman. BMJ Case Rep 2013; pii: bcr2013008558.
(40) Fedele S, Bedogni G, Scoletta M, Favia G, Colella G, Agrillo A, et al. Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed. Br J Oral Maxillofac Surg 2015; 53(1):13-7.
(41) Gupta S, Gupta H, Mandhyan D, Srivastava S. Bisphophonates related osteonecrosis of the jaw. Natl J Maxillofac Surg 2013; 4(2):151-8.
(42) Vidal-Real C, Pérez-Sayáns M, Suárez-Peñaranda J, Gándara-Rey J, García-García A. Osteonecrosis of the jaws in 194 patients who have undergone intravenous bisphosphonate therapy in Spain. Med Oral Patol Oral Cir Bucal 2015; 20(3): e267-e272.
(43) Jowett A, Abdullakutty A, Bailey M.Pathological fracture of the coronoid process secondary to medication-related osteonecrosis of the jaw (MRONJ). Int J Surg Case Rep 2015; 10:162–165.
(44) Huang Y, Ta Chang C, Hsin Muo C, Hao Tsai C, Yu Fu Shen, Zong Wu C. Impact of Bisphosphonate-related Osteonecrosis of the Jaw on Osteoporotic Patients after Dental Extraction: A Population-Based Cohort Study. PLoS ONE 10(4): e0120756.
(45) Matteos N, Caldwell P, Petcu EB, Ivanovski S, Reher P. Dental implant placement with bone augmentation in a patient who received intravenous bisphosphonate treatment for osteoporosis. J Can Dent Assoc 2013; 79:d2.
(46) Coskun Benlidayi I, Guzel R. Oral bisphosphonate related osteonecrosis of the jaw: a challenging adverse effect. ISRN Rheumatol 2013; 2013:215034.
(47) Tosi P, Zamagni E, Cangini D, Tacchetti P, Di Raimondo F, Catalano L et al. Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. Blood 2006; 108(12):3951-2.
(48) Pelaz A, Junquera L, Gallego L, García-Consuegra L, García-Martínez L, Cutilli T, et al. Epidemiology, pharmacology and clinical characterization of bisphosphonate-related osteonecrosis of the jaw. A retrospective study of 70 cases. Acta Otorrinolaringol Esp 2015; 66(3):139-47.
(49) Campisi G, Fedele S, Fusco V, Pizzo G, Di Fede O, Bedogni A.. Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. Future Oncol 2014; 10(2):257-75.
(50) Ikeda T, Kuraguchi J, Kogashiwa Y, Yokoi H, Satomi T, Kohno N. Successful treatment of isphosphonaterelated osteonecrosis of the jaw (BRONJ) patients with sitafloxacin: new strategies for the treatment of BRONJ. Bone 2015; 73:217-22.
(51) Pazianas M, Russell RG, Fogelman I. Osteonecrosis of the jaw: more heat than light. J Nucl Med. 2009; 50(1):6-7.
(52) Kyrgidis A, Andreadis C. Epidemiologic studies are needed to clarify whether dental modalities could be predictors of bisphosphonate osteonecrosis of the jaw in breast cancer patients. Oncologist 2009; 14(1):101-2.
(53) Ripamonti C, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G et al. Decreased occurrence of steonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009; 20(1):137-45.
(54) Kyrgidis A. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol 2008; 26(28):4634-8.
(55) Campisi G, Di Fede O, Musciotto A, Lo Casto A, Lo Muzio L, Fulfaro F, et al. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis. Ann Oncol 2007; 18 Suppl 6:168-72.
(56) Estefania R, Ponte Fernández R, Aguirre Urizar J. Bisphosphonates and oral pathology II. Osteonecrosis of the jaws: review of the literature before 2005. Med Oral Patol Oral Cir Bucal 2006; 11(6):e456-61.
(57) Mellado-Valero A. Implant treatment in patients with osteoporosis. Med Oral Patol Oral Cir Bucal 2010; 15(1):e52-7.
Publicado
Cómo citar
Número
Sección
Licencia
Hasta 2024 utilizamos la licencia Creative Commons Atribución/Reconocimiento-NoComercial 4.0 Internacional https://creativecommons.org/licenses/by-nc/4.0/deed.es. La cual dice que: usted es libre compartir, copiar y redistribuir el material en cualquier medio o formato, también de adaptar, remezclar, transformar y construir a partir del material. Bajo los siguientes términos:
- Atribución: usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios . Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
- NoComercial: usted no puede hacer uso del material con propósitos comerciales .
A partir de 2025 los autores conservan sus derechos de autor y ceden a la revista el derecho de primera publicación de su obra, el cual estará simultáneamente sujeto a la licencia https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es que permite compartir, copiar y redistribuir el material en cualquier medio o formato siempre que se indique la publicación inicial en esta revista. Adaptar, remezclar, transformar y construir a partir del material. Si remezcla, transforma o crea a partir del material, debe distribuir su contribución bajo la la misma licencia del original y no puede hacer uso del material con propósitos comerciales.
Bajo los siguientes términos:
1. Atribución: usted debe dar crédito de manera adecuada, brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
2. NoComercial: usted no puede hacer uso del material con propósitos comerciales.
3. CompartirIgual: si remezcla, transforma o crea a partir del material, debe distribuir su contribución bajo la la misma licencia del original.
PlumX Metrics
.png)
